文献速递类风湿关节炎

类风湿关节炎患者肌少症患病率:采用修订版EWGSOP2与FNIH定义

Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition.
PubMed 文献 · RMD Open · 2022-01-01

这项横断面研究纳入289例≥18岁类风湿关节炎(RA)患者,用双能X线吸收法测四肢瘦体质量,并评估握力、步速与起立时间,按EWGSOP2与FNIH定义判定肌少症,并与280名健康对照的既有数据比较。按EWGSOP2定义,RA患者肌少症患病率为4.5%、对照为0.4%;按FNIH定义为2.8%对0.7%。作者结论认为,按EWGSOP2标准RA患者肌少症较对照更常见,而FNIH定义则在无论是否患RA的高BMI与高脂肪量个体中均发现肌少症。

要点

  • 按EWGSOP2定义,RA患者肌少症患病率4.5%,健康对照0.4%。
  • 按FNIH定义,RA患者患病率2.8%,健康对照0.7%。
  • EWGSOP2定义下,糖皮质激素现用药与肌少症相关(OR 5.25,95%CI 2.14至24.18)。

核心结论

  • 采用EWGSOP2标准时,RA患者肌少症较健康对照显著更常见。
  • FNIH定义在无论是否患RA的高BMI与高脂肪量个体中均显示肌少症。

研究设计与样本

  • 横断面研究,纳入289例≥18岁RA患者,并与280名健康对照的既有数据比较。
  • 采用双能X线吸收法测量四肢瘦体质量,肌肉功能评估包括握力、步速与起立时间。
  • 肌少症分别按修订版EWGSOP2与FNIH定义判定。
  • 研究已在德国临床试验注册中心(DRKS)及WHO临床试验注册平台(ICTRP)注册(DRKS00011873,2017年3月16日注册)。

主要发现

  • 按EWGSOP2定义,4.5%的RA患者(59.4±11.3岁)与0.4%的对照(62.9±11.9岁)患有肌少症。
  • EWGSOP2定义下,与RA患者肌少症相关的因素包括体重(OR 0.92,95%CI 0.86至0.97)、BMI(OR 0.70,95%CI 0.57至0.87)、C反应蛋白(CRP)(OR 1.05,95%CI 1.01至1.10)、病程(OR 1.08,95%CI 1.02至1.36)、当前使用糖皮质激素(OR 5.25,95%CI 2.14至24.18)、泼尼松等效累积剂量(OR 1.04,95%CI 1.02至1.05)与健康评估问卷(HAQ)(OR 2.50,95%CI 1.27至4.86)。
  • 按FNIH定义,RA患者患病率为2.8%、对照为0.7%,与肌少症相关的因素包括身高(OR 0.75,95%CI 0.64至0.88)、BMI(OR 1.20,95%CI 1.02至1.41)、CRP(OR 1.06,95%CI 1.01至1.11)与HAQ(OR 2.77,95%CI 1.17至6.59)。

关键数值与推荐

  • EWGSOP2定义下肌少症患病率:RA患者4.5%,健康对照0.4%。
  • FNIH定义下肌少症患病率:RA患者2.8%,健康对照0.7%。
  • EWGSOP2定义下当前使用糖皮质激素与肌少症的OR为5.25(95%CI 2.14至24.18)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In rheumatoid arthritis (RA), chronic inflammation can enhance the development of sarcopenia with a depletion of muscle mass, strength and performance. Currently, a consensus definition for sarcopenia and solid results for the prevalence of sarcopenia in patients with RA are lacking. METHODS: In this cross-sectional study, 289 patients ≥18 years with RA were recruited. Dual X-ray absorptiometry was performed to measure appendicular lean mass. Assessment of muscle function included grip strength, gait speed and chair rise time. Prevalence of sarcopenia was defined using the updated European Working Group on Sarcopenia in Older People (EWGSOP2) and the Foundation for the National Institutes of Health (FNIH) definition. In addition, the RA study population was compared with existing data of healthy controls (n=280). RESULTS: 4.5% of patients (59.4±11.3 years) and 0.4% of controls (62.9±11.9 years) were affected by sarcopenia according to the EWGSOP2 definition. Body weight (OR 0.92, 95% CI 0.86 to 0.97), body mass index (BMI) (OR 0.70, 95% CI 0.57 to 0.87), C reactive protein (CRP) (OR 1.05, 95% CI 1.01 to 1.10), disease duration (OR 1.08, 95% CI 1.02 to 1.36), current medication with glucocorticoids (OR 5.25, 95% CI 2.14 to 24.18), cumulative dose of prednisone equivalent (OR 1.04, 95% CI 1.02 to 1.05) and Health Assessment Questionnaire (HAQ) (OR 2.50, 95% CI 1.27 to 4.86) were associated with sarcopenia in patients with RA. In contrast, the prevalence was 2.8% in patients compared with 0.7% in controls when applying the FNIH definition, and body height (OR 0.75, 95% CI 0.64 to 0.88), BMI (OR 1.20, 95% CI 1.02 to 1.41), CRP (OR 1.06, 95% CI 1.01 to 1.11) and HAQ (OR 2.77, 95% CI 1.17 to 6.59) were associated with sarcopenia. CONCLUSION: Sarcopenia is significantly more common in patients with RA compared with controls using the EWGSOP2 criteria. The FNIH definition revealed sarcopenia in individuals with high BMI and fat mass, regardless of the presence of RA. TRIAL REGISTRATION NUMBER: It was registered at the German Clinical Trials Registry (DRKS) as well as WHO Clinical Trials Registry (ICTRP) (DRKS00011873, registered on 16 March 2017).

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Dietzel R, Wiegmann S, Borucki D, et al. Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition. RMD Open. 2022. PMID: 36180102. doi:10.1136/rmdopen-2022-002600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。